Risk of Sales Activity Suspension or Restriction Due to COVID-19
First written in FY2020-Q3. 4 of 7 entries say "Mitigated", first in FY2021-Q1. Latest entry: FY2024-Q1.
The whole theme swung hardest in 2020: 23 of 48 companies on the "Worse" side.
18 other companies' latest entry also says "Restated".
- FY2024-Q1RestatedAnnual report
「During the first quarter of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the financial position, operating results or cash flows of the Group among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The Company stated that there had been no material changes concerning the risk of sales activities being suspended or restricted due to COVID-19. - FY2022MitigatedAnnual report
「To maintain business continuity, the Group is taking flexible measures according to infection conditions, including educating employees on infection control, establishing systems that allow various operations to be performed remotely, and permitting work arrangements that reduce infection risk in response to individual employee circumstances.」
The Company continues to identify the impact of infectious diseases on sales and procurement activities as a risk, while putting specific measures in place involving training, remote work, and flexible working arrangements. - FY2021-Q3MitigatedAnnual report
「Regarding conditions in this segment, the impact of COVID-19 on sales activities at medical institutions, the Company's main customers, has eased,」
The Company stated that the impact of COVID-19-related restrictions on sales activities at medical institutions continued to ease. - FY2021-Q2MitigatedAnnual report
「Regarding conditions in this segment, the impact of COVID-19 on sales activities at medical institutions, the Company's main customers, has eased,」
The Company stated that the impact of COVID-19-related restrictions on sales activities at medical institutions had eased. - FY2021-Q1MitigatedAnnual report
「Regarding conditions in this segment, the Company has moved beyond the situation in the previous fiscal year, when COVID-19 made it impossible to conduct sales activities at medical institutions, although」
The Company stated that it had moved beyond the previous fiscal year's situation, in which COVID-19 had suspended sales activities at medical institutions, reducing part of the risk of restrictions on sales activities. - FY2020MaterialisedAnnual report
「As COVID-19 spread, sales activities at medical institutions, the Company's main customers, became impossible, while delays in updates to PACS (medical image management systems) and freezes on negotiations for i-HIS (cloud-based electronic medical records) occurred one after another.」
The suspension of sales activities at medical institutions, delays in PACS updates, and freezes on i-HIS negotiations occurred as COVID-19 spread, affecting business performance. - FY2020-Q3First statedAnnual report
「It is difficult to predict when the COVID-19 pandemic will subside, and the possibility of a second wave or infection among employees and others working for the Company cannot be ruled out. In such cases, sales activities could be suspended or restricted for a certain period, potentially affecting the Company's business performance and other conditions.」
The possibility that a second wave of COVID-19 or infections among employees and others could suspend or restrict sales activities for a certain period has been identified as a business continuity risk for the first time.